drugset / Trial / NCT02182310
Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects
RandomizedCrossoverDouble-blindTreatment
Summary
To demonstrate that BI 201335 does not prolong the QT interval more than placebo. To assess the tolerability of 1200 mg of BI 201335 as single dose in female subjects (double-blind, randomised, placebo-controlled) before inclusion of female subjects in the cross-over part of the trial.
Timeline
- Start
- 2008-06
- Primary completion
- 2008-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Faldaprevir | Small molecule | 480 mg | — |
| Subject | Faldaprevir | Small molecule | 1200 mg | — |
| Comparator | Moxifloxacin | Small molecule | — | — |
Indications
No indication recorded.